AU2010273964A1 - Method of assaying 5-FU - Google Patents

Method of assaying 5-FU Download PDF

Info

Publication number
AU2010273964A1
AU2010273964A1 AU2010273964A AU2010273964A AU2010273964A1 AU 2010273964 A1 AU2010273964 A1 AU 2010273964A1 AU 2010273964 A AU2010273964 A AU 2010273964A AU 2010273964 A AU2010273964 A AU 2010273964A AU 2010273964 A1 AU2010273964 A1 AU 2010273964A1
Authority
AU
Australia
Prior art keywords
sample
patient
inactivator
fluorouracil
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010273964A
Other languages
English (en)
Inventor
Carrie Colvin
Howard Mcleod
Michael Overfield
Benjamin Roa
Salvatore J. Salamone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Publication of AU2010273964A1 publication Critical patent/AU2010273964A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150015—Source of blood
    • A61B5/15003—Source of blood for venous or arterial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
    • A61B5/150236—Pistons, i.e. cylindrical bodies that sit inside the syringe barrel, typically with an air tight seal, and slide in the barrel to create a vacuum or to expel blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
    • A61B5/150244—Rods for actuating or driving the piston, i.e. the cylindrical body that sits inside the syringe barrel, typically with an air tight seal, and slides in the barrel to create a vacuum or to expel blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150351—Caps, stoppers or lids for sealing or closing a blood collection vessel or container, e.g. a test-tube or syringe barrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
    • A61B5/150381—Design of piercing elements
    • A61B5/150389—Hollow piercing elements, e.g. canulas, needles, for piercing the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
    • A61B5/150381—Design of piercing elements
    • A61B5/150503—Single-ended needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
    • A61B5/150534—Design of protective means for piercing elements for preventing accidental needle sticks, e.g. shields, caps, protectors, axially extensible sleeves, pivotable protective sleeves
    • A61B5/150694—Procedure for removing protection means at the time of piercing
    • A61B5/150717—Procedure for removing protection means at the time of piercing manually removed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
    • A61B5/154—Devices using pre-evacuated means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing & Machinery (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AU2010273964A 2009-07-17 2010-07-19 Method of assaying 5-FU Abandoned AU2010273964A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22658909P 2009-07-17 2009-07-17
US61/226,589 2009-07-17
US32424110P 2010-04-14 2010-04-14
US61/324,241 2010-04-14
PCT/US2010/042485 WO2011009140A1 (en) 2009-07-17 2010-07-19 Method of assaying 5-fu

Publications (1)

Publication Number Publication Date
AU2010273964A1 true AU2010273964A1 (en) 2012-02-02

Family

ID=43449866

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010273964A Abandoned AU2010273964A1 (en) 2009-07-17 2010-07-19 Method of assaying 5-FU

Country Status (9)

Country Link
US (1) US8440442B2 (https=)
EP (2) EP2454589A4 (https=)
JP (1) JP5863047B2 (https=)
CN (1) CN102648412A (https=)
AU (1) AU2010273964A1 (https=)
BR (1) BR112012000873A2 (https=)
CA (1) CA2768488A1 (https=)
IN (1) IN2012DN01379A (https=)
WO (1) WO2011009140A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166795A1 (en) * 2011-05-30 2012-12-06 String Therapeutics Inc. Methods and compositions for therapeutic drug monitoring and dosing by point-of-care pharmacokinetic profiling
JP2015502356A (ja) * 2011-11-30 2015-01-22 ウェルスタット ダイアグノスティクス，エルエルシー ５−ｆｕに関連するアッセイ、抗体、免疫原および組成物
US9081001B2 (en) * 2012-05-15 2015-07-14 Wellstat Diagnostics, Llc Diagnostic systems and instruments
WO2015184321A2 (en) * 2014-05-29 2015-12-03 Siemens Healthcare Diagnostics Inc. Rare molecule detection
WO2018232031A1 (en) * 2017-06-14 2018-12-20 Epiphany La Undergarment padding
WO2025015267A1 (en) * 2023-07-13 2025-01-16 Processa Pharmaceuticals, Inc. Methods of personalizing cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225245A1 (en) * 1998-09-29 2007-09-27 Buchsbaum Donald J Viral vector driven mutant bacterial cytosine deaminase gene and uses thereof
ME01335B (me) * 2004-04-29 2013-12-20 Taiho Pharmaceutical Co Ltd Postupak smanjenja gastrointestinalne toksičnosti usled administracije tegafura
PL1774037T3 (pl) * 2004-08-06 2011-09-30 Genentech Inc Oznaczenia i sposoby wykorzystujące biomarkery
NZ555176A (en) * 2004-12-03 2010-03-26 Adherex Technologies Inc Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
US20060177883A1 (en) * 2005-02-08 2006-08-10 Saladax Biomedical Inc. 5-Fluoro-uracil immunoassay
CN101333558A (zh) * 2007-06-29 2008-12-31 上海裕隆生物科技有限公司 5氟尿嘧啶药物敏感基因芯片检测试剂盒

Also Published As

Publication number Publication date
EP3792634A3 (en) 2021-06-02
US8440442B2 (en) 2013-05-14
CN102648412A (zh) 2012-08-22
IN2012DN01379A (https=) 2015-06-05
WO2011009140A1 (en) 2011-01-20
JP2012533739A (ja) 2012-12-27
EP3792634A2 (en) 2021-03-17
BR112012000873A2 (pt) 2019-11-05
US20110034488A1 (en) 2011-02-10
EP2454589A4 (en) 2012-09-05
JP5863047B2 (ja) 2016-02-16
CA2768488A1 (en) 2011-01-20
EP2454589A1 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
US8440442B2 (en) Method of assaying 5-FU
DePalma et al. Optimal serum ferritin level range: Iron status measure and inflammatory biomarker
Geiger et al. Monitoring of clopidogrel action: comparison of methods
MacKeigan et al. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex
Whang et al. The ubiquitin binding protein TAX1BP1 mediates autophagosome induction and the metabolic transition of activated T cells
Sarray et al. Serum IL-6, IL-10, and TNFα levels in pediatric sickle cell disease patients during vasoocclusive crisis and steady state condition
Mahoney et al. Defective metabolism of vitamin B12 in fibroblasts from children with methylmalonicaciduria
Verdoia et al. Diabetes, glucose control and mean platelet volume: a single-centre cohort study
US20200340066A1 (en) Diagnosing idh1 related subgroups and treatment of cancer
Kulkarni et al. Endothelial activation and stress index-measured pretransplantation predicts transplantation-related mortality in patients with thalassemia major undergoing transplantation with Thiotepa, Treosulfan, and fludarabine conditioning
Coggins et al. Pharmacokinetics of GS‐441524 following intravenous remdesivir in six cats and results of therapeutic drug monitoring during treatment of feline infectious peritonitis: 22 cases (2021–2024)
Khurana et al. Comparing clinical characteristics and outcomes of MYC and BCL6 double hit lymphoma (DHL-BCL6) with other aggressive B-cell lymphomas: understanding the impact of new WHO and International Consensus Classifications
Zuurbier et al. Perioperative hyperinsulinaemic normoglycaemic clamp causes hypolipidaemia after coronary artery surgery
Badminton et al. From chemistry to genomics: A concise history of the porphyrias
JPH07504913A (ja) １６員環マクロライド型化合物を含む抗腫瘍活性を有する薬剤
CA2923672A1 (en) Diagnosing idh1 related subgroups and treatment of cancer
HK40048825A (en) Method of assaying 5-fu
Blel et al. Pegylated liposomal doxorubicin (Caelyx®) interference with the spectrophotometric Jaffe method for quantitative determination of creatinine in human plasma
Xie et al. Influence of CDC‑XM and HLA compatibility on clinical outcomes in kidney transplant recipients during the post‑operative recovery period: A retrospective analysis
Wang et al. Heme oxygenase metabolites inhibit tubuloglomerular feedback in vivo
Przybylowski et al. Prevalence of iron deficiency in heart and kidney allograft recipients
CN110776521A (zh) 一种1,2,4-三唑-1,3,4-噻二唑类化合物及其应用
Ragon et al. A phase 1A/B combination study of pegargiminase (ADI-PEG 20), venetoclax and azacitidine in patients with acute myeloid leukemia
Brosi et al. Novel capillary blood point-of-care test for adalimumab and infliximab trough levels: Effects of abnormal blood conditions on the test result
WO2011022174A1 (en) Method of processing blood samples containing 5-fu

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application